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Research Article
Comparative gel-based proteomic analysis
of chemically crosslinked complexes in
dystrophic skeletal muscle
Duchenne muscular dystrophy is a highly progressive muscle wasting disease with a com-
plex pathophysiology that is based on primary abnormalities in the dystrophin gene. In
order to study potential changes in the oligomerization of high-molecular-mass protein
complexes in dystrophic skeletal muscle, chemical crosslinking was combined with mass
spectrometric analysis. The biochemical stabilization of protein interactions was carried
out with the homo-bifunctional and amine-reactive agent bis[sulfosuccinimidyl]suberate,
followed by protein shift analysis in one-dimensional gels. The proteomic approach identi-
fied 11 and 15 protein species in wild type versus dystrophic microsomal fractions, respec-
tively, as well as eight common proteins, with an electrophoretic mobility shift to very high
molecular mass following chemical crosslinking. In dystrophin-deficient preparations,
several protein species with an increased tendency of oligomerisation were identified as
components of the sarcolemma and its associated intra- and extracellular structures, as
well as mitochondria. This included the sarcolemmal proteins myoferlin and caveolin,
the cytoskeletal components vimentin and tubulin, extracellular collagen alpha-1(XII) and
the mitochondrial trifunctional enzyme and oxoglutarate dehydrogenase. These changes
are probably related to structural and metabolic adaptations, especially cellular repair pro-
cesses, which agrees with the increased oligomerisation of myosin-3, myosin-9 and actin,
and their role in cellular regeneration and structural adjustments in dystrophinopathy.
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1 Introduction
The precise assembly and maintenance of supramolecular
protein complexes and dynamic interaction patterns between
protein subunits within membrane structures play key roles
in many basic developmental, metabolic and physiological
processes. It is therefore not surprising that abnormal qua-
ternary protein structures and impaired protein complex for-
mation are involved in the molecular mechanisms that un-
derlie various disease mechanisms. A representative example
of a collapsed protein complex being the disease initiator of a
multifaceted pathological process is the loss of the dystrophin-
glycoprotein complex in the highly progressive neuromus-
cular disorder Duchenne muscular dystrophy [1–3]. The
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primary abnormality in the Dmd gene causes the almost com-
plete loss of its full-length protein product, the Dp427 isoform
of the membrane cytoskeletal protein dystrophin [4], and con-
comitant reduction in all members of the core dystrophin-
associated glycoprotein complex [5].
In healthy muscle tissues, the dystrophin complex pro-
vides a stabilizing linkage between the basal lamina and
the membrane cytoskeleton [6], as well as forms a dynamic
scaffold for signalling mechanisms at the fibre periphery
[7]. A large number of cell biological, biochemical, physi-
ological, transcriptomic and proteomic studies have estab-
lished intricate molecular and cellular changes downstream
of the disintegration of the dystrophin-glycoprotein complex.
An impaired dystrophin assembly clearly destabilizes the
sarcolemma and renders contractile fibres more suscepti-
ble to membrane micro-rupturing, Ca2+-induced necrosis,
impaired excitation-contraction coupling, sterile inflamma-
tion and reactive myofibrosis [8–10]. The complexity of the
dystrophin network and its involvement in the initiation of
progressive fibre wasting in X-linked muscular dystrophy
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therefore warrants a detailed assessment of protein complex
alterations in normal versus dystrophic muscle tissue.
Adaptive or pathobiochemical changes in macromolec-
ular oligomerization can be studied by a variety of highly
advanced bioanalytical techniques, including X-ray crystal-
lography, nuclear magnetic resonance spectroscopy, Förster
resonance energy transfer, and high-resolution cryo-electron
microscopy, as well as yeast two-hybrid screening, differential
co-immuno precipitation analysis, native two-dimensional
gel electrophoresis and gel filtration analysis. Another fre-
quently used approach to profile the structure of protein com-
plexes and interactions within supramolecular assemblies
is chemical crosslinking (XL) [11–13]. In the post-genomic
era, XL analysis and mass spectrometry (MS) have been
successfully combined and are now routinely used as an
integrated technology for structural analyses [14]. The var-
ious methodological variations of crosslinking/mass spec-
trometry (XL/MS) and the establishment of bioinformatics
programs for determining the production of stabile peptide
crosslinks following protein digestion have been extensively
reviewed [15–17]. In contrast to the routine cataloguing of
crosslinked peptides by XL/MS and auxiliary software screen-
ing for the estimation of intra- versus inter-molecular protein
interactions, we have used here a modified XL/MS approach
for comparative purposes.
The analytical workflow consisted of (i) the subcellular
enrichment of microsomal membranes from normal versus
dystrophic muscle, (ii) the stabilization of protein-protein
interactions via the 11.4-Å crosslinker bis[sulfosuccinimi-
dyl]suberate (BS3), (iii) the comparative one-dimensional gel
electrophoretic separation of crosslinked molecules for pro-
tein shift analysis, (iv) in-gel digestion to generate distinct
peptide populations, and (v) the peptide mass spectromet-
ric identification of stabilized proteins that exist in apparent
supramolecular complexes. Thus, in contrast to standardized
XL/MS approaches that directly determine crosslinked pep-
tide structures and involve extensive bioinformatics, this in-
vestigation has determined the effect of muscular dystrophy
on large protein complexes by comparative gel-shift XL analy-
sis. The altered electrophoretic mobility of protein species in
wild type versus mutant muscle membranes in the presence
of an XL agent was investigated in relation to specific molec-
ular mass ranges in polyacrylamide gels. This bioanalytical
approach builds on previous studies that have successfully
combined comparative XL analysis with gel electrophoresis
and immunoblotting [18–20].
The employed XL BS3 is an established analytical agent
in protein biochemistry [21]. BS3 is water-soluble, homo-
bifunctional, non-cleavable and amine-reactive making this
XL molecule especially suitable to stabilize complex protein
structures [22, 23]. The XL-protein conjugation reaction can
be carried out under experimental circumstances that are
relatively close to physiological conditions. The comparative
proteomic study identified a considerable number of protein
species in the dystrophic microsomal fraction that exhibit a
greatly reduced electrophoretic mobility following chemical
crosslinking. Various proteins with an enhanced tendency
for oligomerization were shown to be located in the sar-
colemma, cytoskeletal networks, the extracellular matrix and
mitochondria, and are mostly involved in membrane repair,
fibre regeneration and oxidative metabolism. These findings
suggest that distinct adaptations in critical protein-protein in-
teraction patterns exist that may counter-act progressive fibre
wasting in muscular dystrophy.
2 Materials and methods
2.1 Materials
For the gel-based proteomic profiling of chemically cross-
linked protein species in wild type versus dystrophic mdx-
4cv skeletal muscle, analytical grade reagents and materi-
als were purchased from GE Healthcare (Little Chalfont,
Buckinghamshire, UK), Sigma Chemical Company (Dorset,
UK), Bio-Rad Laboratories (Hemel-Hempstead, Hertford-
shire, UK) and National Diagnostics (Atlanta, GA, USA).
Protease inhibitor cocktails were obtained from Roche Di-
agnostics (Mannheim, Germany). The chemical cross-linker
BS³ and C18 spin columns were supplied by Thermo Fisher
Scientific (Dublin, Ireland). Proteolytic digestion was carried
out with sequencing grade modified trypsin from Promega
(Madison, WI, USA). Biobasic C18 Picofrit columns were
from Dionex (Sunnyvale, CA, USA).
2.2 Preparation of crude microsomes from skeletal
muscle
The preparation of crude microsomes was performed as de-
scribed previously [24]. Skeletal muscle specimens were ob-
tained from the Animal Facility of the University of Bonn
and transported as quick-frozen tissue samples to Maynooth
University on dry ice in accordance with the Department of
Agriculture animal by-product register number 2016/16 (De-
partment of Biology, Maynooth University). Briefly, 0.4 g of
tissue from combined muscles of the hind leg from 5-month
old wild-type C57Bl/6 (n = 4) and age-matched dystrophic
mdx-4cv mice (n = 4) was finely chopped and homogenised
in ten volumes of homogenisation buffer (20 mM sodium
pyrophosphate, 20 mM sodium phosphate, 1 mM MgCl2,
0.303 M sucrose, 0.5 mM EDTA, pH 7.0; supplemented with
a protease inhibitor cocktail [25]), using a hand-held IKA T10
Basic Homogeniser (IKA Labortechnik, Staufen, Germany).
Following homogenisation, crude homogenates were in-
cubated at 4°C for 2 h and then centrifuged at 14 000 × g
for 20 min at 4°C using an Eppendorf 5417 R centrifuge (Ep-
pendorf, Hamburg, Germany). The protein-containing su-
pernatant was carefully isolated and transferred to 4.9 ml
Optiseal tubes. Samples were then centrifuged at 100 000 × g
for 1 h at 4°C using an Optima L-100 XP ultracentrifuge from
Beckman Coulter (Fullerton, CA, USA) [25]. Following ultra-
centrifugation, the resulting supernatant was removed and
the pellet-containing crude microsomes were re-suspended
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in an appropriate volume of homogenisation buffer and
stored at -20°C until required for chemical crosslinking.
2.3 Chemical crosslinking analysis of wild-type
versus mdx-4cv microsomes
Protein concentrations were determined by the method of
Bradford [26] and all samples were diluted to a concentration
of 2 mg protein/ml with 50 mM HEPES, pH 8.0. The water-
soluble cross-linker bis(sulfosuccinimidyl)suberate (BS³) was
dissolved at a concentration of 1mg/ml in 50 mM citrate
buffer, pH 5.0 [18]. Initial optimisation studies were used
to evaluate various concentrations of BS³, including 0.1, 0.5,
1, 2, 5, 7.5, 10, 25, 50, 75, 100 and 150 g cross-linker per
mg protein (not shown). For the main analysis described
in this report, 10 g BS³ per mg protein was selected. Fol-
lowing the addition of BS³, samples were incubated at 25°C
for 30 min. The crosslinking reaction was quenched by the
addition of 50 L 1 M ammonium acetate per ml reaction
mixture [19]. An equal volume of reducing sample buffer was
added and the samples were subsequently heated at 50°C
for 10 min. Crosslinked samples were then electrophoresed
alongside their non-crosslinked counterparts on 1D SDS-
PAGE gels [20]. For silver stain analysis [27], total loading was
10 g protein per lane, while 30 g protein was loaded per
lane for Coomassie staining and subsequent in-gel digestion.
2.4 In-gel digestion of muscle proteins
In-gel digestion for mass spectrometric analysis was per-
formed as per the method of Shevchenko et al. [28]. Pro-
tein lanes were cut into five separate segments A-E and were
processed separately. Individual Coomassie Blue-stained gel
zones were de-stained by the addition of 100 L of 100 mM
ammonium bicarbonate:neat acetonitrile (1:1) solution, and
incubated at 37°C for 30 min with gentle agitation. The solu-
tion was removed and 500 L neat acetonitrile was added
to each gel zone and incubated at room temperature for
10 min with gentle agitation. The solution was removed and
gel pieces then underwent in-gel trypsin digestion. Depend-
ing on the size of the gel piece, 50–100 L of re-suspended
trypsin was added to each gel zone and incubated at 4°C for
30 min to allow slow diffusion of trypsin into the gel. A fur-
ther 20 L of trypsin buffer was added, and gel zones were
incubated for 90 min at 4°C. 40 L of a 50 mM ammonium bi-
carbonate solution was added and left to incubate overnight at
37°C. 100 L extraction buffer [5% formic acid/neat acetoni-
trile (1:2)] was added to gel pieces and incubated at 37°C for
15 min with agitation. The supernatant, containing peptides,
was transferred to fresh tubes, and dried down by vacuum
centrifugation. Dried peptides were re-suspended in 0.5%
TFA/5% ACN, purified by C18 spin columns and dried by
vacuum centrifugation [24]. Dried peptides were stored at
-80°C prior to mass spectrometric analysis.
2.5 Liquid chromatography mass spectrometry
Dried peptides were re-suspended in loading buffer consist-
ing of 2% ACN and 0.05% TFA in LC-MS grade water. The
LC-MS/MS analysis of peptides was performed using an Ul-
timate 3000 NanoLC system (Dionex Corporation, Sunny-
vale, CA, USA) coupled to a Q-Exactive mass spectrometer
(Thermo Fisher Scientific). 300 ng of each digested sample
was loaded by an autosampler onto a C18 trap column (C18
PepMap, 300 m id × 5 mm, 5 m particle size, 100 Å
pore size; Thermo Fisher Scientific). The trap column was
switched on-line with an analytical Biobasic C18 Picofrit col-
umn (C18 PepMap, 75 m id × 50 cm, 2 m particle size,
100 Å pore size; Dionex). Peptides were eluted using a 65 min
method over the following binary gradient [solvent A: (2%
(v/v) ACN and 0.1% (v/v)) formic acid in LC-MS grade water
and solvent B: 80% (v/v) ACN and 0.1% (v/v) formic acid in
LC-MS grade water]: 3% solvent B for 5 min, 3–10% solvent
B for 5 min, 10–40% solvent B for 30 min, 40–90% solvent
B for 5 min, 90% solvent B for 5 min and 3% solvent B for
10 min [29]. The column flow rate was set to 0.3 L/min.
Data were acquired with Xcalibur software (Thermo Fisher
Scientific). The Q-Exactive mass spectrometer was externally
calibrated and operated in positive, data-dependent mode. A
full survey MS scan was performed in the 300–1700 m/z
range with a resolution of 140 000 (m/z 200) and a lock mass
of 445.12003. Collision-induced dissociation (CID) fragmen-
tation was carried out with the fifteen most intense ions per
scan and at 17 500 resolution. A dynamic exclusion window
was applied within 30 s. An isolation window of 2 m/z and
one microscan were used to collect suitable tandem mass
spectra.
2.6 Proteomic identification of muscle-associated
protein species
Qualitative analysis of the mass spectrometry raw files was
performed using Proteome Discoverer 1.4 against Sequest
HT (SEQUEST HT algorithm, licence Thermo Scientific,
registered trademark University of Washington, USA) using
the UniProtKB/Swiss-Prot database, with 25 041 sequences
for mouse (mus musculus). The following search parame-
ters were used for protein identification: (i) peptide mass
tolerance set to 10 ppm, (ii) MS/MS mass tolerance set to
0.02 Da, (iii) an allowance of up to two missed cleavages,
(iv) carbamidomethylation set as a fixed modification and (v)
methionine oxidation set as a variable modification. Peptides
were filtered using a minimum XCorr score of 1.5 for 1, 2.0
for 2, 2.25 for 3 and 2.5 for four charge states, with peptide
probability set to high confidence [30]. For the identification
of common versus unique protein species, proteins were only
considered to be unique if they were detected in all four repli-
cates of one condition and in none of the four replicates in
the other condition. Proteins which are considered common
or shared between control and crosslinked samples are those
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which are detected in all four of the control replicates and all
four of the crosslinked replicates for a given gel piece.
To generate Venn diagrams for the illustration of
common versus unique proteins in the four analyzed cohorts
(wild-type control, wild-type crosslinked, mdx-4cv control and
mdx-4cv crosslinked proteins), Venny 2.1 software (http://bio
infogp.cnb.csic.es/tools/venny/) was used. Potential protein
interactions amongst unique crosslinked proteins in wild-
type and mdx-4cv samples were analyzed by version 10.5 of
the STRING database (http://string-db.org/) for medium
confidence (0.4) interactions with experimental evidence.
The STRING analysis programme clusters proteins based on
known and predicted protein interactions that include direct
physical and indirect functional protein associations [31].
3 Results
3.1 Chemical crosslinking analysis of microsomal
membranes
In order to investigate potential changes in the oligomeric
status of muscle-associated proteins due to deficiency in
the membrane cytoskeletal component dystrophin, chemi-
cal crosslinking was combined with gel electrophoretic shift
analysis and mass spectrometry. The increased tendency
of protein-protein interactions within high-molecular-mass
complexes was determined with the amine-reactive and
homo-bifunctional crosslinker BS3. The flowchart in Fig. 1
outlines the bioanalytical approach used in this study and
shows representative silver-stained gel images of protein
shifting in 1D SDS-PAGE gels following incubation with
the water-soluble and non-cleavable agent BS3. In microso-
mal preparations from both wild-type and dystrophic skele-
tal muscle, increasing XL concentration (0.1–1 and 2–10 g
BS3 per mg protein) triggered distinct changes in the protein
band pattern. Such alterations in the protein banding pattern
included the appearance of intense bands at approximately
150 kDa and above 250 kDa in crosslinked samples, particu-
larly at concentrations of 5, 7.5 and 10 g BS3 per mg protein
(Supporting Information Figs. 1 and 2). Alterations in the pro-
tein composition of different gel regions was carried out by
LC-MS/MS analysis, comparing non-treated wild-type mus-
cle versus XL-incubated wild-type muscle versus non-treated
dystrophic muscle versus XL-incubated dystrophic muscle
preparations.
3.2 Mass spectrometric identification of proteins
with altered electrophoretic mobility
The comparative proteomic approach presented here focused
on the systematic analysis of the XL-induced reduction in gel
electrophoretic mobility of muscle proteins in normal versus
dystrophic skeletal muscle. The shift to gel regions of higher
molecular mass was combined with sensitive MS analysis
and resulted in the unequivocal identification of 346 and 370
protein species in wild-type versus dystrophic preparations,
respectively. Figure 2 summarizes the number of MS-
identified proteins in the high to low molecular mass zones of
the analysed gels, denoted as A to E. The results suggest that a
considerable number of proteins exhibit tight protein-protein
interaction patterns that can be stabilized by incubation with
an XL chemical. Although the majority of microsomal pro-
teins did not undergo a drastic alteration in electrophoretic
mobility following XL treatment, distinct cohorts of protein
species exhibited a BS3-dependent shift to higher molecular
masses. The focus of our proteomic investigation was on
the class of very high-molecular-mass complexes, which
represent various supramolecular assemblies of the muscle
membrane system and its associated intra- and extracellular
structures.
The comparative analysis of the protein species with a
drastically reduced gel electrophoretic mobility following XL
treatment identified 11 and 15 protein species in wild-type ver-
sus dystrophic microsomal fractions, respectively, as well as
8 common proteins in zone A of the Coomassie Blue-stained
gel shown in Fig. 2. The mass spectrometric identification
of altered proteins in normal versus mdx4cv preparations is
listed in Tables 1 and 2, respectively. A list of commonly
detected proteins is presented in Supporting Information
Table 1, and peptide information for Tables 1 and 2 can be
found in Supporting Information Table 2. In addition, files
with the mass spectrometric identification of all proteins in
zones A-E in control versus crosslinked wt samples and con-
trol versus crosslinked mdx-4cv samples (Fig. 2) are available
as Supporting Information Tables 3 and 4.
The exclusive presence of the full-length Dp427 isoform
of dystrophin in the fraction from normal muscle confirmed
the mutant status of the analysed specimens. Other members
of the core dystrophin-glycoprotein complex were not identi-
fied in this gel zone representing extremely high-molecular-
mass assemblies. This is probably due to the relatively low
abundance, small size and hydrophobicity of dystrophin-
associated proteins [2,6]. Additional proteins with a tendency
to form large complexes included various metabolic enzymes,
structural elements, molecular chaperones and transporters.
A large number of very large muscle proteins, such as titin
and the ryanodine receptor calcium release channel, as well
as proteins that naturally form large molecular clusters in-
cluding calcium pumps, contractile proteins and glycolytic
enzymes, are listed in the lower part of Fig. 3 and were shown
to be present in the upper region of SDS-PAGE gels irrespec-
tive of the presence of XL agents.
3.3 Mass spectrometric identification of altered
proteins in muscular dystrophy
In microsomal preparations from mdx-4cv skeletal muscle,
15 protein species with a distinct gel electrophoretic mobil-
ity shift were identified by MS analysis (Table 2). The in-
dividual proteins are located in diverse subcellular regions
such as the sarcolemma, the sarcoplasmic reticulum, the
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Figure 1. Gel-based chemical crosslink-
ing and mass spectrometric analysis
of microsomes from dystrophic skele-
tal muscle. Shown is a flowchart that
outlines the analytical approach to es-
timate increased tendencies of protein
oligomerisation in wild-type (wt) ver-
sus dystrophic mdx-4cv muscle prepa-
rations. In the upper panel, the silver-
stained SDS-PAGE gels represent the
analysis of microsomes that were in-
cubated with 0, 0.1, 0.5 and 1, as well
as 2, 5, 7.5 and 10 g cross-linker bis
(sulfosuccinimidyl)suberate (BS³) per
mg protein in wt versus mdx-4cv prepa-
rations. Lanes 1 to 4 in the silver-
stained gel in the lower panel repre-
sent non-treated wt muscle versus 10 g
BS³/mg protein-incubated wt muscle ver-
sus non-treated mdx-4cv muscle versus
10 g BS³/mg protein-incubated mdx-
4cv muscle preparations, respectively.
Molecular mass standards (in kDa) are
indicated on the left of gel images.
nucleus, the extracellular matrix, the cytoskeleton, the cy-
tosol and mitochondria. Identified proteins fall into the main
functional categories of ion homeostasis, cellular regulation,
structural maintenance, muscle contraction, metabolism and
cellular repair. An increased tendency of oligomerisation was
shown to occur in myosin heavy chain isoforms myosin-3 and
myosin-9, the luminal Ca2+-binding protein sarcalumenin
of the sarcoplasmic reticulum, the elongation factor Tu of
the translational apparatus of mitochondria, the trifunctional
enzyme of the mitochondrial fatty acid beta-oxidation path-
way, tubulin and vimentin, the extracellular matrix collagen
isoform alpha-1(XII), components of the 2-oxoglutarate de-
hydrogenase complex, phosphorylase b kinase, cytoplasmic
actin, the surface membrane protein caveolin-1 and the sar-
colemma repair protein myoferlin (Fig. 3).
3.4 Bioinformatic analysis of proteomic changes in
dystrophic muscle
The bioinformatic analysis using the STRING program [31]
was used to determine whether any of the identified muscle-
associated proteins with an increased tendency to form
oligomeric structures may belong to common complexes,
pathways or cellular processes. Figure 4 shows the findings
from the protein interaction analysis and illustrates that in
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0           10           0           10
g BS3 XL / mg protein
wt mdx-4cv  
A
B
C
D
E
A
B
C
D
E
C XL         C         XL
346 370
Total number of MS-identified microsomal proteins
Number of MS-identified
Protein Species
Number of MS-identified
Protein Species
191 40
362 119
243 86
107 68
126 158
wt
Control
wt
XL
231 35
673 130
426 89
183 70
516 122
mdx-4cv
Control
mdx-4cv
XL
1511 8
wt
XL
mdx-4cv
XL Figure 2. Mass spec-
trometric identification
of crosslinked muscle
proteins with an al-
tered electrophoretic
mobility. Shown is a
Coomassie-stained SDS-
PAGE gel with chemically
crosslinked microsomes
from wild-type (wt) ver-
sus dystrophic mdx-4cv
skeletal muscle. Lanes
1 to 4 are non-treated
wt muscle versus 10 g
BS³/mg protein-incubated
wt muscle versus non-
treated mdx-4cv muscle
versus 10 g BS³/mg
protein-incubated mdx-
4cv muscle preparations,
respectively. The number
of MS-identified proteins
in the high to low molec-
ular mass zones A-E of
the analysed gel lanes
is illustrated by Venn
diagrams.
Table 1. Mass spectrometric identification of proteins with a reduced gel electrophoretic mobility following chemical crosslinking of the
microsomal fraction from wild-type mouse skeletal muscle
Accession number Protein name Percentage coverage Unique peptides
P11531 Dystrophin Dp427 5.98 17
Q3V1D3 AMP deaminase 1 19.06 9
P11499 Heat shock protein HSP 90-beta 8.98 6
O08638 Myosin-11 5.83 6
Q9Z1E4 Glycogen [starch] synthase, muscle 8.27 5
Q91YQ5 Dolichyl-diphosphooligosaccharide–protein glycosyltransferase subunit 1 9.05 4
Q9R0Y5 Adenylate kinase isoenzyme 1 23.2 3
P97447 Four and a half LIM domains protein 1 11.07 3
P43274 Histone H1.4 15.53 2
P04247 Myoglobin 21.43 2
O88492 Perilipin-4 12.83 2
normal muscle a minor hub appears to exist between the heat
shock protein Hsp90, myosin-11, adenylate kinase isoform
AK1 and AMP deaminase 1. The protein interaction analysis
of highly oligomerised protein species in dystrophin-deficient
microsomes suggests a cluster of up-regulated myosin heavy
chains and the cytoskeletal proteins vimentin and tubulin.
Potential pathways include the membrane repair and wound
healing complex consisting of myoferlin, caveolin, actin and
myosin, which is probably involved in compensatory fi-
bre regeneration processes to counteract progressive muscle
wasting. The increased complex formation of mitochondrial
enzymes involved in fatty acid oxidation and the citric acid
cycle indicates metabolic adaptations in dystrophic fibres.
4 Discussion
The almost complete loss of the membrane cytoskeletal
protein dystrophin renders skeletal muscle fibres more sus-
ceptible to necrosis. The disintegration of the dystrophin-
associated glycoprotein complex causes sarcolemmal insta-
bility, which in turn results in abnormal Ca2+-fluxes and
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Table 2. Mass spectrometric identification of proteins with a reduced gel electrophoretic mobility following chemical crosslinking of the
microsomal fraction from dystrophic mdx-4cv mouse skeletal muscle
Accession number Protein name Percentage coverage Unique peptides
Q8BMS1 Trifunctional enzyme subunit alpha, mitochondrial 19.92 13
Q8VDD5 Myosin-9 7.4 13
Q7TQ48 Sarcalumenin 17.25 12
Q60597 2-oxoglutarate dehydrogenase, mitochondrial 14.71 12
Q60847 Collagen alpha-1(XII) chain 5.1 7
Q8BFR5 Elongation factor Tu, mitochondrial 16.81 6
Q99JY0 Trifunctional enzyme subunit beta, mitochondrial 12.84 6
Q9D2G2 Dihydrolipoyllysine-residue succinyltransferase component of 2-oxoglutarate
dehydrogenase complex, mitochondrial
8.37 4
Q7TSH2 Phosphorylase b kinase regulatory subunit beta 5.25 4
P13541 Myosin-3 19.38 3
P49817 Caveolin-1 19.05 3
Q69ZN7 Myoferlin 1.92 3
P60710 Actin, cytoplasmic 1 26.4 2
P99024 Tubulin beta-5 chain 15.32 2
P20152 Vimentin 9.23 2
Dystrophin Dp427 
AMP deaminase 1 
Heat shock protein HSP 90-beta 
Myosin-11 
Glycogen synthase 
Glycosyltransferase RPN-I
Adenylate kinase AK1
Four and a half LIM domains protein 1 
Histone H1.4 
Myoglobin 
Perilipin-4 
Trifunctional enzyme, alpha and beta
Myosin-3  Myosin-9 
Sarcalumenin
2-oxoglutarate dehydrogenase subunits
Collagen alpha-1(XII) chain
Elongation factor Tu
Phosphorylase b kinase
Caveolin-1 Myoferlin
Actin, cytoplasmic
Tubulin beta-5
Vimentin 
Myosin-7  Myosin-8
MICOS complex subunit Mic60 
Isocitrate dehydrogenase
Collagen alpha-2(VI) chain 
Nidogen-1 
Polyubiquitin-B 
Tubulin beta-4B 
wt
11 proteins
mdx-4cv
15 proteins
wt & mdx-4cv
8 proteins
Proteins identified in chemically cross-linked high molecular mass complexes
Unaltered protein species in high-molecular-mass complexes
Titin - Ryanodine receptor RyR1 - Myosin-1/Myosin-4 - Ca-ATPase SERCA1/SERCA2 - Glycogen phosphorylase - ATP 
synthase subunit alpha/beta - Creatine kinase M-type - Phosphofructokinase - Plectin - Actinin, alpha-3 - Pyruvate kinase -
ADP/ATP translocase - Myomesin-1 - Aldolase - Laminin, gamma-1 - Tropomyosin, alpha-1 - Glyceraldehyde-3-phosphate 
dehydrogenase - Myosin-binding protein C, fast - Collagen alpha-1(I)/ alpha-2(I) - Myosin light chain MLC1/3 and MLC2 –
Albumin - Enolase - Fibrillin-1 - Tropomyosin, beta - Actin, alpha
Figure 3. Overview of muscle protein species with a drastically reduced gel electrophoretic mobility following chemical crosslinking anal-
ysis. Shown are comparative listings of proteins with a tendency to increased oligomerisation in normal versus dystrophic microsomes.
Details of the MS-based identification of altered proteins in control versus mdx-4cv preparations are listed in Tables 1 and 2, respectively.
high levels of proteolytic degradation [10]. Progressive mus-
cle wasting, sterile inflammation and reactive myofibrosis are
characteristic features of X-linked muscular dystrophy. These
complex pathophysiological changes are reflected by distinct
proteome-wide alterations, encompassing a large spectrum
of proteins involved in ion handling, signal transduction, the
excitation-contraction-relaxation cycle, the innate immune re-
sponse, bioenergetic pathways, metabolic regulation and the
cellular stress response [24, 25, 30, 32–36]. The findings of
the combined XL and MS study presented here suggest that
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Figure 4. Bioinformatic anal-
ysis of proteomic changes
in the microsomal fraction
from dystrophic muscle.
Shown are the findings from
the bioinformatic analysis
of protein interactions us-
ing STRING [31] software
programs.
numerous muscle-associated proteins with an altered abun-
dance also exhibit a changed oligomerisation pattern. A va-
riety of physiological regulators, structural components and
repair molecules showed a drastically increased tendency to
form protein-protein interactions in response to dystrophin
deficiency.
In contrast to conventional gel electrophoretic shift anal-
yses, which routinely employ immunoblotting for the detec-
tion of altered mobility patterns [18–20], the method outlined
in this report has used the more reliable MS-based identi-
fication of changes in muscle proteins. Often monoclonal
or monospecific antibodies to monomeric subunits do not
recognize their respective antigen(s) in XL-stabilized protein
complexes, making the determination of the range of protein
oligomerisation difficult. In addition, hypothesis-driven im-
munoblotting surveys following XL incubation with a select
number of antibodies are inherently biased. As shown in this
technology-driven study, the number of altered proteins with
a change in their oligomeric status is considerable. In compar-
ison to the relatively limited scope of immunoblot analyses,
the efficient and unequivocal identification of protein changes
by the highly sensitive LC-MS/MS method is more compre-
hensive and can be combined with systems bioinformatics.
The increased tendency of oligomerisation of different
components of the mitochondrial trifunctional enzyme and
the oxoglutarate dehydrogenase complex is an interesting
finding in relation to potential metabolic changes and bioen-
ergetic adaptations in muscular dystrophy. The trifunctional
enzyme complex of the inner mitochondrial membrane sys-
tem is an important component that mediates fatty acid
utilization and altered enzymatic functionality has severe
pathophysiological consequences [37]. A previous survey of
crude microsomal membranes by MS-based proteomics has
revealed elevated levels of this metabolic enzyme in
dystrophin-deficient skeletal muscle tissue [38]. The 2-oxo-
glutarate dehydrogenase complex is a multi-enzyme assem-
bly of the mitochondrial matrix that catalyses the over-
all conversion of 2-oxoglutarate to succinyl-CoA and CO2
as a crucial part of the citric acid cycle in skeletal mus-
cle [39]. Oxoglutarate dehydrogenase also undergoes stress-
mediated changes and may therefore play a role in the
cellular stress response [40]. The analysis of muscle cell cul-
tures from Duchenne patients and dystrophin-deficient ani-
mal models has revealed structural changes in mitochondria
and altered activity levels of antioxidant and mitochondrial en-
zymes [41,42]. Based on these observations, an attractive and
alternative pathomechanism to the main calcium hypothesis
of dystrophinopathy has been suggested, i.e. systemic mito-
chondrial impairments play a key role in X-linked muscular
dystrophy [43]. Thus, the increased complex formation of the
mitochondrial trifunctional enzyme and the oxoglutarate de-
hydrogenase may represent an adaptive process to counter-act
impaired lipid metabolism and insufficient ATP production
in dystrophic fibres. Mitochondrial dysfunction appears to
contribute to the pathological muscle wasting syndrome by
reducing availability of ATP needed for essential calcium reg-
ulation and fibre regeneration [44]. In addition, various XL-
stabilised protein species were shown to be present in both
normal and dystrophic muscle fractions, including compo-
nents of the sarcomere such as myosin heavy chain isoforms
7 and 8, the protein degradation element polyubiquitin-B,
metabolic enzymes and the cytoskeletal tubulin subunit beta-
4B, as well as the extracellular matrix components nidogen-1
and collagen alpha-2(VI).
Importantly, the MS-based identification of muscular
dystrophy-related changes in protein oligomerisation agrees
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with the identification of altered protein species in previous
comparative proteomic surveys of dystrophic skeletal mus-
cles [24, 30, 35, 38]. The XL-focused investigation described
here suggests that the loss of the membrane cytoskeletal
protein dystrophin and resulting sarcolemmal instability is
probably compensated by the up-regulation of the cytoskele-
tal proteins vimentin and tubulin in the fibre interior [30]. Al-
though high concentration levels of vimentin are usually only
transiently observed during the maturation of myotubes [45],
this cytoskeletal protein can act synergistically to desmin [46].
The compensatory increase in vimentin, which appears to oc-
cur in all dystrophic muscle subtypes [47], and the elevated
levels of vimentin protein interaction levels, as indicated by
the findings of the XL analysis described in this report, sug-
gests a vimentin-associated support of the structural back-
bone of intermediate filaments. This probably restores, at
least partially, the load-bearing function of contractile fibres
in the absence of the cytoskeletal dystrophin lattice.
The changes in myoferlin are most likely related to the
initiation of cellular repair processes. Myoferlin and dysfer-
lin are involved in important regulatory processes, including
transverse tubule formation and Ca2+-handling in skeletal
muscles [48]. In conjunction with annexins and actin, the
repair proteins myoferlin and dysferlin play an important
role in skeletal muscle membrane fusion and restoration
mechanisms in muscular dystrophy [49]. The efficient re-
sealing of the dystrophin-deficient sarcolemma by vesicular
patching presents a key protective response in muscular dys-
trophy. This process is probably supported by the increased
oligomerisation of various isoforms of myosin and actin, as
shown here by XL analysis. The above listed proteins are ma-
jorly involved in cellular regeneration and structural adapta-
tions in dystrophinopathy. The increased oligomerisation of
caveolin-1 would agree with its elevated concentration in mdx
muscle and increased numbers of vesicular invaginations of
the sarcolemma, called caveolae, in dystrophic muscles [50].
Caveolae structures are involved in signalling processes and
endocytic trafficking, and changes in caveolin proteins appear
to be related to regenerative processes [10, 51].
In conclusion, the combination of chemical crosslink-
ing, electrophoretic gel-shift analysis and mass spectrometry
has been successfully applied to compare the tendency of
protein oligomerisation in normal versus dystrophic skeletal
muscle tissue. A variety of muscle-associated protein species
were shown to exhibit an elevated level of cluster formation.
This included proteins involved in oxidative metabolism, ion
homeostasis, membrane repair and fibre regeneration. The
majority of these alterations in protein interaction patterns
are probably in response to the loss of sarcolemmal integrity
and represent compensatory mechanisms to rescue the dys-
trophic phenotype. In the future, the systematic establish-
ment of these types of proteome-wide changes might be ex-
ploitable to establish novel biomarker candidates for the im-
proved diagnosis, prognosis and/or therapy-monitoring in
the field of muscular dystrophy.
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